To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have DLBCL that has recurred or progressed despite prior therapy. Note that certain types of DLBCL may be excluded.
- Patients must have had high-dose chemotherapy and autologous stem cell transplantation or be ineligible for this therapy.
- At least 3 weeks must have passed since completion of prior therapy and receipt of the study drug.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. John Gerecitano at 212-639-3748.